AI-Based Mobile Intervention on Medication Non-Adherence and Transition (NCT07445074) | Clinical Trial Compass
RecruitingNot Applicable
AI-Based Mobile Intervention on Medication Non-Adherence and Transition
United States200 participantsStarted 2026-05
Plain-language summary
This study aims to examine whether the AI-personalized version of the Medilepsy® app is more effective than the non-AI (standard version without AI personalization) can improve key outcomes, such as medical adherence and transition readiness, among underserved adolescents and young adults with epilepsy, ages 14-24, in Florida, USA.
Outcomes are organized into primary (effectiveness), secondary (usability), and exploratory (language experience) endpoints.
Who can participate
Age range14 Years – 24 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Diagnosed with epilepsy
* Currently prescribed anti-seizure medicine (ASMs)
* Identified as part of an underserved population, defined as meeting at least one of the following: member of a racial or ethnic group historically underrepresented in research or healthcare or low-income status (e.g., eligible for public assistance or government-subsidized health coverage)
* Are between 14-17 years old and able to provide assent, with a parent or LAR present to receive app notifications throughout the study
* Are between 18-24 years old and able to provide informed consent
* Able to read, speak, and write in English
* Resides in Florida
* Receive outpatient medical services
Exclusion Criteria:
* They do not own a mobile device with internet access.
* They have a history of severe intellectual disability.
* They are unable to operate a mobile device (keyboard or touchscreen).
* Reside in an in-patient setting.
* Adults unable to consent.
* Pregnant women (excluded because pregnancy is not relevant to the study focus).
* Prisoners.
What they're measuring
1
Examine the effect of Medilepsy® with and without responsible AI design on medication adherence.